Compounds > capecitabine
Page last updated: 2024-08-24

capecitabine and incb-018424

capecitabine has been researched along with incb-018424 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beck, JT; Bendell, JC; Clark, J; Garrett, WM; Hunter, DS; Hurwitz, HI; Leopold, L; Levy, RS; Manges, R; Nemunaitis, JJ; Pipas, JM; Sandor, V; Stella, PJ; Uppal, N; Wade, SM; Wagner, SA; Wainberg, ZA1
Bendell, J; Clark, J; Dawkins, F; Greeno, E; Hidalgo, M; Hurwitz, H; Li, CP; Macarulla, T; O'Reilly, EM; Sahai, V; Salvo, MG; Sama, A; Van Cutsem, E; Verslype, C; Walker, C; Yu, KH1
DeMichele, A; Diab, S; Geschwindt, R; Jiang, W; Kalinsky, K; Kennealey, G; Ma, CX; O'Shaughnessy, J; Richards, P; Rugo, HS; Steis, R; Wright, GS; Yardley, DA1

Trials

3 trial(s) available for capecitabine and incb-018424

ArticleYear
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-01, Volume: 33, Issue:34

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Pancreatic Neoplasms; Prognosis; Pyrazoles; Pyrimidines; Survival Rate

2015
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
    Investigational new drugs, 2018, Volume: 36, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Nitriles; Pancreatic Neoplasms; Pyrazoles; Pyrimidines

2018
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    Breast cancer research and treatment, 2018, Volume: 170, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C-Reactive Protein; Capecitabine; Female; Humans; Inflammation Mediators; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Proportional Hazards Models; Pyrazoles; Pyrimidines; Receptor, ErbB-2; Treatment Outcome; Young Adult

2018